Back

Symptomatic endpoint responder rates to BAROSTIM Therapy

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Chronic Heart Failure ePosters Devices for Autonomic Modulation ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor William Abraham

The Ohio State University, Columbus (United States of America)

274 More presentations in this session

Presentation thumbnail
Increased myocardial fat supply improves cardiac energetics and function in heart failure
Doctor W. Watson (Cambridge, GB)
Abstract Slides
Presentation thumbnail
Cardiac aging is regulated by autophagic disorder mediated by chronic inflammation via the Rubicon/NOX4 pathway.
Doctor T. Kamihara (Obu, JP)
Abstract Slides
Presentation thumbnail
Participants with diabetes have less augmentation in cardiac function and energetics in response to increased supply of fatty acid
Doctor P. Green (Hobart, AU)
Abstract Slides
Presentation thumbnail
Impaired high-density lipoprotein function in patients with heart failure
Ms L. Emmens (Groningen, NL)
Abstract Slides
Presentation thumbnail
The comparison of clinical significance between atrial and ventricular structural remodeling in patients with heart failure with preserved ejection fraction - insights from PURSUIT-HFpEF registry
Doctor M. Okada (Osaka, JP)
Abstract Slides

Access the full session

Session thumbnail
Chronic Heart Failure ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of cardiac resinchronization therapy on long term outcomes of patients with heart failure and depressed left ventricular ejection fraction
29 June 2021
thumbnail
Congress Session
Unlocking the potential of baroreflex activation therapy (BAT) for HFrEF patients
29 August 2022
thumbnail
Congress Presentation
Chemoreflex and baroreflex dysfunction still predict cardiovascular mortality and hospitalizations in patients with systolic heart failure and up-to-date treatment
29 June 2021
thumbnail
Congress Presentation
Levosimendan single dose responder: clinical profile and outcomes
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources